Table 4.
Outcomes of subjects treated with secondary immunosuppression
| Age/sex | Indication | Prior to 1st (TAC/GCs) |
Prior to cCTX/GCs |
2 mo |
4 mo |
6 mo |
aPLA2R (RU/ml) |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proteinuria (g/d) | Serum albumin (g/dl) | Proteinuria (g/d) | Serum albumin (g/dl) | Proteinuria (g/d) | Serum albumin (g/dl) | Proteinuria (g/d) | Serum albumin (g/dl) | Proteinuria (g/d) | Serum albumin (g/d) | 1 | 2 | 3 | ||
| 24/M | Resistant | 2.30 | 1.62 | 4.70 | 2.90 | 2.50 | 2.32 | 1.20 | 3.59 | 0.6 | 4.32 | 0.45a | 27.27 | 0.10 |
| 45/M | Resistant | 10.30 | 1.42 | 3.00 | 2.16 | 2.40 | 1.80 | 2.70 | 2.07 | 3.00 | 2.19 | 938.21 | 201.95 | 182.39 |
| 26/M | Resistant | 6.60 | 1.80 | 7.50 | 2.47 | 1.30 | 3.05 | 0.76 | 4.10 | 0.71 | 3.68 | 217.09 | 186.67 | 52.23 |
| 41/F | Relapse | 5.00 | 2.20 | 4.20 | 2.91 | 3.76 | 2.64 | 0.86 | 3.65 | 0.88 | 4.01 | 203.46 | 364.23 | 0.81 |
| 18/F | Resistant | 5.70 | 1.50 | 3.90 | 2.59 | 4.50 | 1.10 | 1.50 | 2.16 | 2.50 | 2.48 | 1468.54 | 440.92 | 359.30 |
| 22/M | Relapse | 7.38 | 1.90 | 11.50 | 2.62 | 2.40 | 3.21 | 1.40 | 3.57 | 0.80 | 4.10 | 118.80 | 235.18 | 0.37 |
| 55/M | Resistant | 6.23 | 4.40 | 14.70 | 3.19 | 3.20 | 3.70 | 2.01 | 3.80 | 0.28 | 3.96 | 0.45a | 156.51 | 0.29 |
| 45/F | Relapse | 7.40 | 2.40 | 5.00 | 2.83 | 1.00 | 3.42 | 0.15 | 4.50 | 0.20 | 4.13 | 21.41 | 32.52 | 0.31 |
| 48/M | Relapse | 6.00 | 1.85 | 4.00 | 2.77 | 1.50 | 2.20 | 1.00 | 3.90 | 0.96 | 3.90 | 50.55 | 135.90 | 0.59 |
| Age/sex | Indication | Prior to 1st (CTX/GCs) |
Prior to TAC |
6 mo |
12 mo |
18 mo |
aPLA2R (RU/ml) |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proteinuria (g/d) | Serum albumin (g/dl) | Proteinuria (g/d) | Serum albumin (g/dl) | Proteinuria (g/d) | Serum albumin (g/dl) | Proteinuria (g/d) | Serum albumin (g/dl) | Proteinuria (g/d) | Serum albumin (g/dl) | 1 | 2 | 3 | ||
| 40/M | Resistant | 7.50 | 1.58 | 4.60 | 3.80 | 1.90 | 4.00 | 2.80 | 3.72 | 7.92 | 2.85 | 350.87 | 71.83 | 142.34 |
| 58/F | Resistant | 4.40 | 2.95 | 3.80 | 2.70 | 2.50 | 3.42 | 4.86 | 3.10 | 5.18 | 3.35 | 393.01 | 76.72 | 55.19 |
| 54/M | Resistant | 4.00 | 2.20 | 4.63 | 2.60 | 4.30 | 2.90 | 4.60 | 2.20 | Expired | Expired | 0.45 | 0.45 | NA |
| Age/sex | Indication | Prior to primary IST |
Prior to rituximab |
2 mo |
4 mo |
6 mo |
aPLA2R (RU/ml) |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proteinuria (g/d) | Serum albumin (g/dl) | Proteinuria (g/d) | Serum albumin (g/dl) | Proteinuria (g/d) | Serum albumin (g/dl) | Proteinuria (g/d) | Serum albumin (g/dl) | Proteinuria (g/d) | Serum albumin (g/dl) | 1 | 2 | 3 | ||
| 45/Mb | Resistant | 6.50 | 2.42 | 3.46 | 2.59 | 1.2 | 2.48 | 4.5 | 3.13 | 4.31 | 3.15 | 326.73 | 578.30 | 138.87 |
| 48/Fb | Relapse | 4.40 | 2.50 | 3.50 | 2.60 | 3.23 | 3.46 | 0.92 | 3.48 | 0.53 | 3.60 | 337.16 | 221.71 | 0.85 |
| 18/Mb | Resistant | 6.29 | 1.90 | 4.00 | 1.90 | 1.80 | 2.12 | 2.00 | 2.02 | 3.67 | 2.72 | 841.25 | 144.89 | 16.18 |
| 34/Mc | Resistant | 14.80 | 2.40 | 4.20 | 3.25 | 2.40 | 3.54 | 0.08 | 4.04 | 1.62 | 4.07 | 61.32 | 101.85 | 3.14 |
| 60/Fb | Relapse | 3.10 | 2.40 | 5.16 | 3.30 | 2.44 | 3.50 | 1.08 | 3.70 | 1.83 | 3.80 | 214.13 | 322.37 | 7.70 |
Time frames are as follows: 1—before starting primary immunosuppression, 2—before starting second line agent, 3—at completion of second line agent (6 months for patients who received CTX/GCs or rituximab as second line agent and 12 months for those who received tacrolimus as second line agent).
aPLA2R, antibodies to m-type phospholipase A2 receptor; cCTX, cyclical cyclophosphamide; F, female; GCs, glucocorticoids; IST, immunosuppressive therapy; M, male; NA, not available; RU, resonance unit; TAC, tacrolimus.
Cases with baseline aPLA2R negative, but serial aPLA2R positive (also had enhanced staining for PLA2R in glomeruli positive).
Primary immunosuppression was TAC/GCs.
Primary immunosuppression was cCTX/GCs.